Posts

Showing posts with the label drugs

Huons Secures Therapex’s TRX-211 NSCLC Drug

Image
Therapex, a domestic biotech company, has transferred the technology for TRX-211, a novel non-small cell lung cancer (NSCLC) drug candidate it developed in-house, to Huons. Huons announced on the 23rd that it had signed a contract to introduce TRX-211, a targeted anticancer candidate for non-small cell lung cancer, NSCLC, developed by Therapex, thereby expanding its research and development pipeline. Under the contract, the company will lead the clinical development of TRX-211, which is in the preclinical stage, and will hold domestic rights after approval. It also has the option to exercise rights for global distribution in the future. TRX-211 is an oral tyrosine kinase inhibitor (TKI) targeting epithelial growth factor receptor (EGFR) Exon20 insertion mutation non-small cell lung cancer, NSCLC. Lung cancer is classified as small cell lung cancer when the cancer cells are small and non-small cell lung cancer when they are larger. Huons introduced TRX-211, anticipating that it could pr...